Home  |  Contact

Cellosaurus MDA-MB-231-Dox (CVCL_UJ21)

[Text version]

Cell line name MDA-MB-231-Dox
Synonyms MDA-231-Dox
Accession CVCL_UJ21
Resource Identification Initiative To cite this cell line use: MDA-MB-231-Dox (RRID:CVCL_UJ21)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Sequence variations Heterozygous for BRAF p.Gly464Val (c.1391G>T) (ClinVar=VCV000040364) (from parent cell line).
Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (from parent cell line).
TERT c.228C>T (-124C>T); in promoter (from parent cell line).
Homozygous for TP53 p.Arg280Lys (c.839G>A) (ClinVar=VCV000376657) (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0062 (MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
Publications

PubMed=7902062
de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J.
Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
Anticancer Res. 13:1425-1430(1993)

Cross-references
Other Wikidata; Q95987366
Entry history
Entry creation25-Feb-2019
Last entry update02-Jul-2020
Version number3